|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Ossareh-Nazari B, Bachelerie F and
Dargemont C: Evidence for a role of CRM1 in signal-mediated nuclear
protein export. Science. 278:141–144. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukuda M, Asano S, Nakamura T, Adachi M,
Yoshida M, Yanagida M and Nishida E: CRM1 is responsible for
intracellular transport mediated by the nuclear export signal.
Nature. 390:308–311. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stommel JM, Marchenko ND, Jimenez GS, Moll
UM, Hope TJ and Wahl GM: A leucine-rich nuclear export signal in
the p53 tetramerization domain: regulation of subcellular
localization and p53 activity by NES masking. EMBO J. 18:1660–1672.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saji M, Vasko V, Kada F, Allbritton EH,
Burman KD and Ringel MD: Akt1 contains a functional leucine-rich
nuclear export sequence. Biochem Biophys Res Commun. 332:167–173.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Watt PJ, Maske CP, Hendricks DT,
et al: The Karyopherin proteins, Crm1 and Karyopherin β1, are
overexpressed in cervical cancer and are critical for cancer cell
survival and proliferation. Int J Cancer. 124:1829–1840. 2009.
|
|
8
|
Noske A, Weichert W, Niesporek S, et al:
Expression of the nuclear export protein chromosomal region
maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian
cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao Y, Dong Y, Lin F, et al: The
expression of CRM1 is associated with prognosis in human
osteosarcoma. Oncol Rep. 21:229–235. 2009.PubMed/NCBI
|
|
10
|
Shen A, Wang Y, Zhao Y, Zou L, Sun L and
Cheng C: Expression of CRM1 in human gliomas and its significance
in p27 expression and clinical prognosis. Neurosurgery. 65:153–159.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH
and Sun YJ: Prognostic value of CRM1 in pancreas cancer. Clin
Invest Med. 32:E3152009.PubMed/NCBI
|
|
12
|
Zhou F, Qiu W, Yao R, et al: CRM1 is a
novel independent prognostic factor for the poor prognosis of
gastric carcinomas. Med Oncol. 30:7262013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tai YT, Landesman Y, Acharya C, et al:
CRM1 inhibition induces tumor cell cytotoxicity and impairs
osteoclastogenesis in multiple myeloma: molecular mechanisms and
therapeutic implications. Leukemia. 28:155–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roberts BJ, Hamelehle KL, Sebolt JS and
Leopold WR: In vivo and in vitro anticancer activity of the
structurally novel and highly potent antibiotic CI-940 and its
hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 16:95–101.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mutka SC, Yang WQ, Dong SD, Ward SL, Craig
DA, Timmermans PB and Murli S: Identification of nuclear export
inhibitors with potent anticancer activity in vivo. Cancer Res.
69:510–517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Neck T, Pannecouque C, Vanstreels E,
Stevens M, Dehaen W and Daelemans D: Inhibition of the
CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates:
structure-activity relationship and mechanism of action. Bioorg Med
Chem. 16:9487–9497. 2008.PubMed/NCBI
|
|
17
|
Allred DC, Brown P and Medina D: The
origins of estrogen receptor α-positive and estrogen receptor
α-negative human breast cancer. Breast Cancer Res. 6:240–245.
2004.
|
|
18
|
Maae E, Nielsen M, Steffensen KD, Jakobsen
EH, Jakobsen A and Sorensen FB: Estimation of immunohistochemical
expression of VEGF in ductal carcinomas of the breast. J Histochem
Cytochem. 59:750–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT
method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones GJ, Heiss NS, Veale RB and Thornley
AL: Amplification and expression of the TGF-α, EGF receptor and
c-myc genes in four human oesophageal squamous cell carcinoma
lines. Biosci Rep. 13:303–312. 1993.
|
|
21
|
Shimada Y, Imamura M, Wagata T, Yamaguchi
N and Tobe T: Characterization of 21 newly established esophageal
cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kudo N, Khochbin S, Nishi K, Kitano K,
Yanagida M, Yoshida M and Horinouchi S: Molecular cloning and cell
cycle-dependent expression of mammalian CRM1, a protein involved in
nuclear export of proteins. J Biol Chem. 272:29742–29751. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van der Watt PJ and Leaner VD: The nuclear
exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and
repressed by p53 in response to DNA damage. Biochim Biophys Acta.
1809:316–326. 2011.PubMed/NCBI
|
|
24
|
Casson AG, Tammemagi M, Eskandarian S,
Redston M, McLaughlin J and Ozcelik H: p53 alterations in
oesophageal cancer: association with clinicopathological features,
risk factors, and survival. Mol Pathol. 51:71–79. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uchino S, Saito T, Inomata M, Osawa N,
Chikuba K, Etoh K and Kobayashi M: Prognostic significance of the
p53 mutation in esophageal cancer. Jpn J Clin Oncol. 26:287–292.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lecane PS, Kiviharju TM, Sellers RG and
Peehl DM: Leptomycin B stabilizes and activates p53 in primary
prostatic epithelial cells and induces apoptosis in the LNCaP cell
line. Prostate. 54:258–267. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smart P, Lane EB, Lane DP, Midgley C,
Vojtesek B and Lain S: Effects on normal fibroblasts and
neuroblastoma cells of the activation of the p53 response by the
nuclear export inhibitor leptomycin B. Oncogene. 18:7378–7386.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuusisto HV, Wagstaff KM, Alvisi G, Roth
DM and Jans DA: Global enhancement of nuclear
localization-dependent nuclear transport in transformed cells.
FASEB J. 26:1181–1193. 2011. View Article : Google Scholar : PubMed/NCBI
|
